2,818 Shares in Novo Nordisk A/S $NVO Acquired by Atlantic Union Bankshares Corp

Atlantic Union Bankshares Corp acquired a new stake in Novo Nordisk A/S (NYSE:NVO) in the second quarter, Holdings Channel reports. The fund acquired 2,818 shares of the company’s stock, valued at approximately $194,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of NVO. Stone House Investment Management LLC bought a new position in shares of Novo Nordisk A/S in the 1st quarter worth $30,000. NewSquare Capital LLC raised its holdings in Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after buying an additional 282 shares during the last quarter. Disciplina Capital Management LLC lifted its stake in shares of Novo Nordisk A/S by 162.3% in the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock valued at $33,000 after buying an additional 297 shares in the last quarter. Dagco Inc. bought a new position in shares of Novo Nordisk A/S in the first quarter valued at $35,000. Finally, Mid American Wealth Advisory Group Inc. acquired a new position in shares of Novo Nordisk A/S during the second quarter valued at about $37,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $45.62 on Monday. The company has a market capitalization of $203.69 billion, a PE ratio of 12.53, a PEG ratio of 2.33 and a beta of 0.65. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The stock’s 50 day moving average price is $55.32 and its 200-day moving average price is $61.51. Novo Nordisk A/S has a twelve month low of $45.05 and a twelve month high of $112.52.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The business had revenue of $11.74 billion for the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Berenberg Bank upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Wednesday, September 17th. UBS Group downgraded Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 5th. Rothschild Redb upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 16th. Dbs Bank raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, August 22nd. Finally, BMO Capital Markets reiterated a “market perform” rating and set a $55.00 price target (up previously from $50.00) on shares of Novo Nordisk A/S in a report on Tuesday, October 14th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $59.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.